Iowanews Headlines

Treatment Resistant Depression (TRD) – Pipeline Insight, 2026

DelveInsight’s “Treatment Resistant Depression (TRD) – Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies developing several pipeline drugs in the Treatment Resistant Depression pipeline landscape. It covers the TRD pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Treatment Resistant Depression treatment landscape. Learn more about the evolving TRD pipeline today @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Treatment Resistant Depression Pipeline Report

• In April 2026, the FDA approved Neurolief Inc’s ProlivRx, the first physician-directed, at-home brain neuromodulation therapy for adjunctive treatment in adults with MDD who failed to achieve satisfactory improvement from at least one previous antidepressant.

• In April 2026, research data showed that BPL-003 for the treatment of treatment-resistant depression continued to demonstrate sustained symptom reduction.

• In Quarter 1, 2026, COMPASS Pathways reported positive Phase 3 efficacy results for COMP360 psilocybin in treatment-resistant depression, demonstrating a 3.6-point mean MADRS advantage over placebo.

• In Quarter 1, 2026, Biohaven reported that BHV-7000 failed to demonstrate a reduction of depressive symptoms in a Phase 2 proof-of-concept study evaluating major depressive disorder (MDD).

• Treatment-resistant depression is defined as major depressive episodes that fail to show satisfactory improvement after at least two different antidepressant monotherapy trials, affecting over one-third of patients with MDD.

• DelveInsight’s report depicts a diversifying clinical pipeline with 25+ active players advancing therapies targeting NMDA receptors, glutamate modulation, and neuroactive steroids.

• The leading Treatment Resistant Depression companies include Janssen Pharmaceuticals, Merck, Novartis, COMPASS Pathways, Axsome Therapeutics, and Sage Therapeutics.

• The TRD market size is expected to grow to USD 2.33 billion in 2026, driven by rapid commercial uptake of novel-mechanism therapies like esketamine and maturing real-world evidence.

Download for updates and the latest revolution in TRD care @ Treatment Resistant Depression Market Insight, Epidemiology And Market Forecast

Treatment Resistant Depression Emerging Drugs Profile

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, NMDA receptor antagonist being developed by Axsome Therapeutics for the treatment of treatment-resistant depression. It utilizes a proprietary formulation of dextromethorphan and bupropion designed to modulate the glutamate system and offer a different mechanism from standard serotonergic approaches. AXS-05 is part of a new class of rapid-acting antidepressants aiming to provide symptom relief for patients who fail standard SSRI/SNRI therapies.

COMP360: COMPASS Pathways

COMP360 is a synthesized psilocybin formulation being developed by COMPASS Pathways for use in psychedelic-assisted therapy. It is currently in Phase 3 clinical evaluation for treatment-resistant depression, where it has demonstrated significant symptom reduction and improved emotional processing in controlled medical settings. COMP360 has received FDA Breakthrough Therapy designation, reflecting its potential as a transformative therapy for mental health conditions with high unmet need.

Esketamine (Spravato): Janssen Pharmaceuticals

Esketamine is a rapid-acting NMDA receptor antagonist administered as a nasal spray. It was initially approved for treatment-resistant depression in conjunction with an oral antidepressant and received a label expansion in January 2025 to include monotherapy. Esketamine works on the glutamate system to reduce symptoms within hours to days and is increasingly recognized for its ability to reduce suicidal thoughts rapidly.

For more information on the Treatment Resistant Depression Emerging Drugs Profile, download DelveInsight’s comprehensive Treatment Resistant Depression Pipeline Insight report.

The Treatment Resistant Depression Pipeline Report Provides

• Detailed insights about companies developing therapies for Treatment Resistant Depression, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for TRD treatment.

• TRD companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• TRD drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Treatment Resistant Depression market.

Learn more about Treatment Resistant Depression drug opportunities in our comprehensive TRD pipeline report @ Treatment Resistant Depression Unmet Needs

Treatment Resistant Depression Companies and Competitive Landscape

There are 25+ key companies, including Janssen Pharmaceuticals, Merck, Novartis, Sage Therapeutics, Axsome Therapeutics, and COMPASS Pathways, developing therapies for Treatment Resistant Depression, with several novel-mechanism drugs currently in Phase III clinical evaluation.

DelveInsight’s Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

• Molecule Type

Treatment Resistant Depression products have been categorized under various Molecule types such as:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Discover the latest advancements in Treatment Resistant Depression treatment by visiting our website. Stay informed @ Treatment Resistant Depression Market Drivers and Barriers, and Future Perspectives

Scope of the Treatment Resistant Depression Pipeline Report

• Coverage: Global.

• Treatment Resistant Depression Companies: Janssen Pharmaceuticals, Merck, Novartis, Sage Therapeutics, Axsome Therapeutics, COMPASS Pathways, and others.

• Treatment Resistant Depression Therapies: AXS-05, COMP360, Esketamine (Spravato), and other undisclosed pipeline candidates.

• Treatment Resistant Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.

• Treatment Resistant Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Table of Contents

1. Introduction

2. Executive Summary

3. Treatment Resistant Depression: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Treatment Resistant Depression – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Treatment Resistant Depression Key Companies

13. Treatment Resistant Depression Key Products

14. Treatment Resistant Depression Unmet Needs

15. Treatment Resistant Depression Market Drivers and Barriers

16. Treatment Resistant Depression Future Perspectives and Conclusion

17. Treatment Resistant Depression Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services